ArticleJournal of experimental & clinical cancer research : CR2022

Depleting receptor tyrosine kinases EGFR and HER2 overcomes resistance to EGFR inhibitors in colorectal cancer.

Lu Yang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.